Abstract #4664

129Xe MRI Assessment of Disease Progression in Patients with COPD treated with Azithromycin: Multi-Site Repeatability and Preliminary Results

Jaime Mata¹, John Mugler III¹, Bastiaan Driehuys², David Mummy², Laura Bell³, Alexandre Coimbra³, Paula Belloni³, Peter Niedbalski⁴, and Yun Michael Shim¹

¹University of Virginia, Charlottesville, VA, United States, ²Duke University, Durham, NC, United States, ³Genentech, San Francisco, CA, United States, ⁴University of Kansas, Lawrence, KS, United States

Synopsis

Keywords: Lung, Hyperpolarized MR (Gas), COPD, clinical trial

Harmonization of imaging methodology among three sites was successfully achieved.

Preliminary results for longitudinal treatment with azithromycin demonstrated the sensitivity of 129Xe MRI in detecting ventilation changes, presumably caused by Sars-Cov2 infection or termination of azithromycin treatment at week 24 due to hearing loss. This preliminary data supports that 129Xe MRI is a sensitive tool for detecting subtle changes in COPD early and may potentially reduce the length of clinical trials that aim to visualize therapeutic responses.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.